Breaking News, Collaborations & Alliances

ARTBIO, PharmaLogic Enter Manufacturing and Supply Pact

PharmaLogic will assist with radiochemistry and supply of the finished radiopharmaceutical product for clinical trials of AB001.

PharmaLogic Holdings Corp., a radiopharmaceutical CDMO, and ARTBIO, a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs), entered into a manufacturing and supply agreement for ARTBIO’s lead-212 (212Pb) based radiopharmaceutical candidate, AB001, for the treatment of prostate cancer. PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB0...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters